KPTIQStockKaryopharm Therapeutics Inc.
Verdicts genuinely change. Free email alert the moment KPTIQ's does — no target price to set, unlike a price alert.
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2026-06-30. These ratios come from the issuer's own published statements rather than structured SEC data.
AAOIFI divides by the market cap stored with these figures ($465,107); this record does not say which day it was fetched, so no estimate for today is made from it.
Business activity: not screened
We have not screened this company's line of business, so these ratios say nothing about whether what it does is permissible.
AAOIFI Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 1 of 1 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Non-permissible income | 1.90% | 5.00% | Pass(3.1pp buffer) |
Usmani Fail 2 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing investments | 49.68% | 33.00% | Fail(16.7pp over) |
| Non-liquid assets | 23.49% | at least 20.00% | Pass(3.5pp above the floor) |
| Non-permissible income | 1.90% | 5.00% | Pass(3.1pp buffer) |
MSCI Fail 1 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 49.68% | 33.33% | Fail(16.3pp over) |
| Accounts receivable | 76.51% | 33.33% | Fail(43.2pp over) |
| Non-permissible income | 1.90% | 5.00% | Pass(3.1pp buffer) |
FTSE Fail 1 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 49.68% | 33.33% | Fail(16.3pp over) |
| Accounts receivable | 76.51% | 50.00% | Fail(26.5pp over) |
| Non-permissible income | 1.90% | 5.00% | Pass(3.1pp buffer) |
ℹ️ Dow Jones Islamic Market, MSCI M-Series, S&P Shariah divide by a trailing-average market cap (24- or 36-month) rather than today's. That price history is not collected for non-US listings, so these are reported as unverified — it reflects a missing input on our side, not anything about the company.
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from KPTIQ's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $146.1M | 2025-12-31 | RevenueFromContractWithCustomerExcludingAssessedTax |
| Interest-bearing debtBorrowings — which definition was stored is not recorded | not measured | — | — |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $55.3M | 2026-06-30 | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
| Total assetsBalance sheet total | $111.3M | 2026-06-30 | Assets |
| Market capDenominator for AAOIFI | $465.1K | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | not measured | — | — |
| 24-month average market capDenominator for Dow Jones Islamic Market | not measured | — | — |
| Non-permissible revenueInterest and excluded income | $2.8M | 2025-12-31 | InvestmentIncomeInterest |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Sources
Filing information. Balance sheet as of 2026-06-30. Income statement as of 2025-12-31. Screened 2026-11-14.
Filing links appear after the next screen: this row was screened before filing citations were recorded.
-
Total assets$111.3M
Assets· balance sheet as of 2026-06-30 -
Cash and interest-bearing securities$55.3M
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents· balance sheet as of 2026-06-30 -
Receivables$29.9M
ReceivablesNetCurrent· balance sheet as of 2026-06-30 -
Revenue$146.1M
RevenueFromContractWithCustomerExcludingAssessedTax· income statement as of 2025-12-31 -
Interest income (non-permissible)$2.8M
InvestmentIncomeInterest· income statement as of 2025-12-31 -
Market cap$465.1KMarket-data quote at screen time, 2026-11-14 · not a filing figure, so no link
What changed, and when
Verdict history for KPTIQ. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-09-07 No change recorded No verdict change for KPTIQ has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.
Tracked since 2026-09-07.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Griffin | Citadel Advisors | $0M | 0.0% | 2026-09-30 |
| David Shaw | D. E. Shaw & Co. | $0M | 0.0% | 2026-09-30 |
| Israel Englander | Millennium Management | $0M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| ROC (10) | -55.57 | SELL |
| Momentum (10) | -0.05 | SELL |
| EMA (10) | 0.05 | SELL |
| SMA (10) | 0.04 | SELL |
| EMA (20) | 0.05 | SELL |
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. On November 2, 2026, Karyopharm Therapeutics Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.
Background via Yahoo Finance — informational, not part of the verdict.
Weak — low conviction, small size or skip
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 🕐 1H | NEUTRAL | 24 |
| ⏱ 15-Min | NEUTRAL | 98 |
| ⏲ 5-Min | RANGING | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Still fetching insider filings — it ran past this page's budget, so the page painted without waiting. The fetch is still running; reload in a moment and it will be here.
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-10 · Asset managers net 914130 (-14454)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.